<p>圣地亚哥，2025 年 12 月 10 日（全球新闻稿）——Crinetics Pharmaceuticals, Inc.（纳斯达克：CRNX）今天宣布，在 2025 年 12 月 10 日，董事会薪酬委员会授予了非合格股票期权奖励，购买其普通股总计 39,575 股，并向 9 名新非执行员工授予了总计 26,525 股限制性股票单位（“RSU”）奖励，均根据 Crinetics Pharmaceuticals, Inc. 2021 年就业诱导激励奖励计划（“2021 年诱导计划”）进行。股票期权和 RSU 的授予是为了吸引员工与 Crinetics 签订雇佣合同，符合纳斯达克上市规则 5635(c)(4)。</p>
<p>2021 年诱导计划专门用于向之前不是 Crinetics 员工的个人授予股权奖励，或在经过真实的非就业期后，作为吸引这些个人与 Crinetics 签订雇佣合同的诱因，符合纳斯达克上市规则 5635(c)(4)。股票期权的行使价格为每股 48.06 美元，等于 2025 年 12 月 10 日 Crinetics 普通股在纳斯达克全球精选市场的收盘价。股票期权所涉及的股份将在四年内归属，其中 25% 的股份将在适用归属开始日期的一周年纪念日归属，其余股份将在之后的 36 个连续的相等月度分期中归属，前提是每位员工在这些归属日期继续在 Crinetics 工作。RSU 将在四年内以相等的年度分期归属，从适用归属开始日期的一周年纪念日开始，同样前提是每位员工在这些归属日期继续在 Crinetics 工作。股票期权和 RSU 奖励受 2021 年诱导计划的条款和条件以及适用的股票期权奖励协议或 RSU 奖励协议的条款和条件的约束。</p>
<p><strong>关于 Crinetics Pharmaceuticals</strong></p>
<p>Crinetics Pharmaceuticals 是一家全球制药公司，致力于通过以患者需求为基础的科学，转变内分泌疾病和内分泌相关肿瘤的治疗。Crinetics 专注于发现、开发和商业化新疗法，核心专长是利用小分子靶向 G 蛋白偶联受体（GPCRs），这些小分子具有特定定制的药理学和特性。</p>
<p>Crinetics 的主打产品 PALSONIFY™（paltusotine）是美国 FDA 批准的首个每日一次的口服治疗方案，适用于对手术反应不足的成人肢端肥大症患者，或手术不适合的患者。Paltusotine 还在临床开发中，针对与神经内分泌肿瘤相关的类癌综合症。Crinetics 的深厚管线包括 10 多个已披露的项目，其中包括晚期研究候选药物 atumelnant，目前正在针对先天性肾上腺增生和 ACTH 依赖性库欣综合症进行晚期开发。其他发现项目涉及多种内分泌疾病，如神经内分泌肿瘤、格雷夫斯病（包括格雷夫斯甲状腺功能亢进和格雷夫斯眼病，即甲状腺眼病）、多囊肾病、甲状旁腺功能亢进、糖尿病、肥胖症和 GPCR 靶向的肿瘤指征。</p>
<p><strong>投资者：</strong></p>
<p>Gayathri Diwakar</p>
<p>投资者关系负责人</p>
<p>gdiwakar@crinetics.com</p>
<p>（858）345-6340</p>
<p><strong>媒体：</strong></p>
<p>Natalie Badillo</p>
<p>企业传播负责人</p>
<p>nbadillo@crinetics.com</p>
<p>（858）450-6464</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01ETXpPU00zTXpFMk5EVTRJekl3T0RrNE1UVT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01ETXpPU00zTXpFMk5EVTRJekl3T0RrNE1UVT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YTM0NDc1YzQtMjY2My00MGViLTg0NzktNjM4NjM1ZjE3MGNiLTExMDEzODYtMjAyNS0xMi0xMC1lbg==/tiny/Crinetics-Pharmaceuticals-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YTM0NDc1YzQtMjY2My00MGViLTg0NzktNjM4NjM1ZjE3MGNiLTExMDEzODYtMjAyNS0xMi0xMC1lbg==/tiny/Crinetics-Pharmaceuticals-Inc-.png"/></p>

CRNX

<p>Crinetics Pharmaceuticals 宣布根据纳斯达克上市规则 5635(c)(4) 提供诱因奖励，向新员工授予股票期权和限制性股票单位（RSUs），作为其 2021 年诱因计划的一部分。股票期权的行使价格为 48.06 美元，并将在四年内逐步归属。Crinetics 专注于内分泌疾病的治疗，并拥有丰富的项目管道，包括用于肢端肥大症的 PALSONIFY™ 和用于先天性肾上腺增生的 atumelnant</p>

<p>SAN DIEGO , Dec. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 39,575 shares of its common stock and granted an aggregate of 26,525 restricted stock unit (“RSU”) awards to 9 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>圣地亚哥，2025 年 12 月 10 日（全球新闻稿）——Crinetics Pharmaceuticals, Inc.（纳斯达克：CRNX）今天宣布，在 2025 年 12 月 10 日，董事会薪酬委员会授予了非合格股票期权奖励，购买其普通股总计 39,575 股，并向 9 名新非执行员工授予了总计 26,525 股限制性股票单位（“RSU”）奖励，均根据 Crinetics Pharmaceuticals, Inc. 2021 年就业诱导激励奖励计划（“2021 年诱导计划”）进行。股票期权和 RSU 的授予是为了吸引员工与 Crinetics 签订雇佣合同，符合纳斯达克上市规则 5635(c)(4)。</p>
</div><p>The 2021 Inducement Plan is used exclusively for granting equity awards to individuals who were not previously employees of Crinetics, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Crinetics, pursuant to Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $48.06 per share, which is equal to the closing price of Crinetics’ common stock on the Nasdaq Global Select Market on December 10, 2025. The shares subject to the stock options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter, subject to each employee’s continued employment with Crinetics on such vesting dates. The RSUs will vest over four years in equal annual installments beginning on the one-year anniversary of the applicable vesting commencement date, also subject to each employee’s continued employment with Crinetics on such vesting dates. The stock option and RSU awards are subject to the terms and conditions of the 2021 Inducement Plan and the terms and conditions of an applicable stock option award agreement or RSU award agreement covering the respective grant.</p>
<div class="lb-trans"><p>2021 年诱导计划专门用于向之前不是 Crinetics 员工的个人授予股权奖励，或在经过真实的非就业期后，作为吸引这些个人与 Crinetics 签订雇佣合同的诱因，符合纳斯达克上市规则 5635(c)(4)。股票期权的行使价格为每股 48.06 美元，等于 2025 年 12 月 10 日 Crinetics 普通股在纳斯达克全球精选市场的收盘价。股票期权所涉及的股份将在四年内归属，其中 25% 的股份将在适用归属开始日期的一周年纪念日归属，其余股份将在之后的 36 个连续的相等月度分期中归属，前提是每位员工在这些归属日期继续在 Crinetics 工作。RSU 将在四年内以相等的年度分期归属，从适用归属开始日期的一周年纪念日开始，同样前提是每位员工在这些归属日期继续在 Crinetics 工作。股票期权和 RSU 奖励受 2021 年诱导计划的条款和条件以及适用的股票期权奖励协议或 RSU 奖励协议的条款和条件的约束。</p>
</div><p><strong>About Crinetics Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>关于 Crinetics Pharmaceuticals</strong></p>
</div><p>Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.</p>
<div class="lb-trans"><p>Crinetics Pharmaceuticals 是一家全球制药公司，致力于通过以患者需求为基础的科学，转变内分泌疾病和内分泌相关肿瘤的治疗。Crinetics 专注于发现、开发和商业化新疗法，核心专长是利用小分子靶向 G 蛋白偶联受体（GPCRs），这些小分子具有特定定制的药理学和特性。</p>
</div><p>Crinetics’ lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics’ deep pipeline of 10+ disclosed programs includes late-stage investigational candidate atumelnant, which is currently in late-stage development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. Additional discovery programs address a variety of endocrine conditions such as neuroendocrine tumors, Graves’ disease (including Graves’ hyperthyroidism and Graves’ orbitopathy, or thyroid eye disease), polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications.</p>
<div class="lb-trans"><p>Crinetics 的主打产品 PALSONIFY™（paltusotine）是美国 FDA 批准的首个每日一次的口服治疗方案，适用于对手术反应不足的成人肢端肥大症患者，或手术不适合的患者。Paltusotine 还在临床开发中，针对与神经内分泌肿瘤相关的类癌综合症。Crinetics 的深厚管线包括 10 多个已披露的项目，其中包括晚期研究候选药物 atumelnant，目前正在针对先天性肾上腺增生和 ACTH 依赖性库欣综合症进行晚期开发。其他发现项目涉及多种内分泌疾病，如神经内分泌肿瘤、格雷夫斯病（包括格雷夫斯甲状腺功能亢进和格雷夫斯眼病，即甲状腺眼病）、多囊肾病、甲状旁腺功能亢进、糖尿病、肥胖症和 GPCR 靶向的肿瘤指征。</p>
</div><p><strong>Investors:</strong></p>
<div class="lb-trans"><p><strong>投资者：</strong></p>
</div><p>Gayathri Diwakar</p>
<div class="lb-trans"><p>Gayathri Diwakar</p>
</div><p>Head of Investor Relations</p>
<div class="lb-trans"><p>投资者关系负责人</p>
</div><p>gdiwakar@crinetics.com</p>
<div class="lb-trans"><p>gdiwakar@crinetics.com</p>
</div><p>(858) 345-6340</p>
<div class="lb-trans"><p>（858）345-6340</p>
</div><p><strong>Media:</strong></p>
<div class="lb-trans"><p><strong>媒体：</strong></p>
</div><p>Natalie Badillo</p>
<div class="lb-trans"><p>Natalie Badillo</p>
</div><p>Head of Corporate Communications</p>
<div class="lb-trans"><p>企业传播负责人</p>
</div><p>nbadillo@crinetics.com</p>
<div class="lb-trans"><p>nbadillo@crinetics.com</p>
</div><p>(858) 450-6464</p>
<div class="lb-trans"><p>（858）450-6464</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZd01ETXpPU00zTXpFMk5EVTRJekl3T0RrNE1UVT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYwMDMzOSM3MzE2NDU4IzIwODk4MTU="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YTM0NDc1YzQtMjY2My00MGViLTg0NzktNjM4NjM1ZjE3MGNiLTExMDEzODYtMjAyNS0xMi0xMC1lbg==/tiny/Crinetics-Pharmaceuticals-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/YTM0NDc1YzQtMjY2My00MGViLTg0NzktNjM4NjM1ZjE3MGNiLTExMDEzODYtMjAyNS0xMi0xMC1lbg==/tiny/Crinetics-Pharmaceuticals-Inc-.png"/></p>

Crinetics Pharmaceuticals 宣布根据纳斯达克上市规则 5635(c)(4) 授予 2025 年 12 月的激励性授予 | CRNX 股票新闻